Freenome's First Print: $60 Million of Net Income, and $2–4 Million of Revenue Next Quarter
The Abbott license turned a pre-revenue cancer-screening startup into a profitable public company on paper. The fourth-quarter guide is where the story actually starts.
FRNM · Earnings Call · 2026-11-10
A quarter that was mostly a signature
Freenome's debut earnings call as a public company carried a headline number that would flatter a mid-cap medtech: $183.5 million of total revenue against $1 million a year earlier, operating income of $70 million, net income of $60.1 million, or $0.58 a share, and $117.9 million of adjusted EBITDA. Almost none of it came from selling tests. Of that revenue, $182.5 million was license and collaboration revenue, and $180 million of it was recognized under the Abbott agreement following FDA approval of SimpleScreen CRC — $157.5 million for the exclusive commercialization license plus a $22.5 million cumulative catch-up for earlier periods. Cash flow followed the same script: the $35.7 million of free cash flow includes the $100 million milestone payment from Abbott.
With the commercial launch still in its early stages, we do not expect meaningful testing revenue or royalties in the fourth quarter.
That is the whole tension in one sentence. Fourth-quarter revenue is guided to $2 million–$4 million — R&D fees from Abbott, U.K. service revenue, and gross-margin-neutral lab processing fees. So the company's true commercial run rate, one month into the Abbott launch, is roughly one-fiftieth of the quarter it just reported. The first print is a balance-sheet event dressed as an income statement; the second print will be the business.
One small crack worth flagging: the CFO, pressed on the $157 million license line, answered that "that $167.5 relates to the commercial contract we have with Abbott" — a $10 million gap from the prepared remarks. Likely a transposition in the live answer, but on a first call with a first-ever revenue line, precision matters.
The fundamentals on file still describe a shell
The data trail complicates the story further. The most recent quarterly filing covers a period ended July 15, 2026 — before the business combination closed — and it depicts an entity with essentially no operations: operating income of roughly negative $0.9 million and a net loss in the low hundreds of thousands. Liabilities to assets sit at 8.2%, up 4.2 points year over year, with the trend line rising steadily since 2024. Free cash flow less stock comp has been a persistent small negative across the entire history.
In other words, there is no comparable prior quarter to benchmark against. The $430 million of cash and securities, the "into 2028" runway, the $885 million Abbott ceiling with $242.2 million already received and $642.8 million still contingent — all of it is new this quarter. Investors are underwriting a contract, not a track record.
Sixty million unscreened, twenty reps, and Abbott's 800
The commercial architecture is the genuinely interesting part. Abbott took over standalone U.S. commercialization of blood-based CRC screening on September 30, trained roughly 800 reps, and began working a 380,000-provider channel. Freenome's own contribution is a top-down push into the roughly 600 U.S. health systems — and that team currently numbers about 20 people, per the CEO's answer to a question about scaling. Management frames a long-term commercial organization "probably in the $400 million range," which reads as an annual spend figure rather than a headcount, and which nobody on the call pressed him to clarify.
The early indicators are encouraging but thin: more than 2,000 clinical sites requested collection kits in the first 30 days, electronic ordering integrations were slated to go live in November, and Abbott is negotiating pricing with most of the top 20 payers. Guidance and reimbursement are converging in Freenome's favor — the ACS guidelines added SimpleScreen CRC in August, Medicare set an initial $920 price, and UnitedHealthcare, Carelon, and Cigna/EviCore have all moved. The global theme tape agrees that blood based biomarkers is where money is flowing, and peer guideline inclusion is the operative catalyst across the diagnostics complex — Guardant, a direct comparable in this reporter set, leaned on the same lever for its colorectal cancer screen.
But the honest framing is this: per current ACS guidance, colonoscopy and stool-based tests remain preferred, and blood is the option for the unwilling. Asked directly whether Abbott's stool product goes first in the bag, the CEO answered that the test is "complementary" to stool and that the target is the 60 million people who get nothing at all. That is a defensible market — and it is also a second-line market for now.
The version-two clock is the number to watch
The most consequential disclosure was buried in the reimbursement plumbing. The 10% royalty only starts once SimpleScreen CRC hits a 20% gross margin; before that Freenome takes 50% of gross margin. Management explicitly declined to put timing on it, tied it to cost of goods scaling with volume and to Abbott's ASP strategy, and conceded the $920 Medicare price and the coding strategy were chosen to maximize adoption rather than near-term economics. An ADLT re-rate is parked until version two.
And version two is late. The next-gen assay is a real improvement — high-grade dysplasia sensitivity up from 30.5% to 41.9%, overall advanced precancerous lesion sensitivity from 13.7% to 18.2%, with CRC sensitivity holding at 80.4% at 90% specificity. The supplemental PMA goes in by year-end, approval is guided to mid-2027, but the Abbott tech transfer — and the $70 million milestone attached to it — has slid into the first half of 2028. Until Abbott's lab is FDA-approved to run it, Freenome runs every sample itself, which is a capacity constraint and a margin constraint simultaneously.
Meanwhile the lung launch is deliberately cheap: a protein-only assay, with 82% stage-one sensitivity and a 99.8% negative predictive value, positioned to funnel patients into low dose CT. The multiomics IVD waits on PROACT Lung. When an analyst asked whether the protein version gets retired, nobody quite said yes. Investors are effectively being asked to believe the attach rate story — roughly 20% overlap between CRC and lung cancer populations, with the promise that a menu of single cancer tests plus an asymptomatic multi-cancer readout in mid-2027 compounds value per patient sample. That is a plausible flywheel. It is also, for now, a slide.